Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NT 501

X
Drug Profile

NT 501

Alternative Names: Ciliary neurotrophic factor - Neurotech; Ciliary neurotrophic factor implant - Neurotech; CNTF implant - Neurotech; Encapsulated CNTF - Neurotech; NT-501; Retinitis pigmentosa encapsulated cell therapy - Neurotech; Rexenus

Latest Information Update: 07 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neurotech USA
  • Developer National Eye Institute; Neurotech USA; Stanford University; University of Miami
  • Class Cell therapies; Eye disorder therapies; Gene therapies
  • Mechanism of Action Ciliary neurotrophic factor replacements; Neurogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinal telangiectasis; Retinitis pigmentosa
  • New Molecular Entity No

Highest Development Phases

  • Phase III Retinal telangiectasis
  • Phase II/III Retinitis pigmentosa
  • Phase II Glaucoma; Usher syndromes
  • Phase I/II Colour vision defects
  • No development reported Dry macular degeneration; Optic nerve disorders

Most Recent Events

  • 02 May 2024 Neurotech Pharmaceuticals plans a phase III trial for Retinal telangiectasis in the US (Intraocular, Implant) (NCT06397131)
  • 22 Feb 2023 Phase III development for Retinal telangiectasis is ongoing in Australia, France, United Kingdom, USA and Germany (Intraocular, Implant)
  • 03 Nov 2022 Pooled efficacy and adverse events data from a phase III Protocol A and Protocol B trial Retinal (macular) telangiectasis released by Neurotech Pharmaceuticals
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top